Last updated on October 2018

A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma


Brief description of study

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU- 554 administered orally in patients with FGF19 IHC+ hepatocellular carcinoma (HCC). The study consists of 3 parts, a dose-escalation part (Part 1), an expansion part (Part 2) exploring a once daily (qd) dosing schedule at the recommended Phase 2 dose (RP2D), and a Part 3 expansion of the qd dosing schedule at the RP2D in TKI naive patients.

Clinical Study Identifier: NCT02508467

Contact Investigators or Research Sites near you

Start Over

Blueprint Medicines

Hospital Beaujon
Clichy, France
3.18miles
  Connect »

Blueprint Medicines

Institut Gustave Roussy
Villejuif, France
9.91miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.